Literature DB >> 23355369

A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.

Gheorghe Doros1, Michael Pencina, Denis Rybin, Allison Meisner, Maurizio Fava.   

Abstract

Previous authors have proposed the sequential parallel comparison design (SPCD) to address the issue of high placebo response rate in clinical trials. The original use of SPCD focused on binary outcomes, but recent use has since been extended to continuous outcomes that arise more naturally in many fields, including psychiatry. Analytic methods proposed to date for analysis of SPCD trial continuous data included methods based on seemingly unrelated regression and ordinary least squares. Here, we propose a repeated measures linear model that uses all outcome data collected in the trial and accounts for data that are missing at random. An appropriate contrast formulated after the model has been fit can be used to test the primary hypothesis of no difference in treatment effects between study arms. Our extensive simulations show that when compared with the other methods, our approach preserves the type I error even for small sample sizes and offers adequate power and the smallest mean squared error under a wide variety of assumptions. We recommend consideration of our approach for analysis of data coming from SPCD trials.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23355369     DOI: 10.1002/sim.5728

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Placebo Response and Practice Effects in Schizophrenia Cognition Trials.

Authors:  Richard S E Keefe; Vicki G Davis; Philip D Harvey; Alexandra S Atkins; George M Haig; Owen Hagino; Stephen Marder; Dana C Hilt; Daniel Umbricht
Journal:  JAMA Psychiatry       Date:  2017-08-01       Impact factor: 21.596

2.  Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Ella J Daly; Jaskaran B Singh; Maggie Fedgchin; Kimberly Cooper; Pilar Lim; Richard C Shelton; Michael E Thase; Andrew Winokur; Luc Van Nueten; Husseini Manji; Wayne C Drevets
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

3.  Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).

Authors:  Maurizio Fava; Marlene P Freeman; Martina Flynn; Bettina B Hoeppner; Richard Shelton; Dan V Iosifescu; James W Murrough; David Mischoulon; Cristina Cusin; Mark Rapaport; Boadie W Dunlop; Madhukar H Trivedi; Manish Jha; Gerard Sanacora; Gretchen Hermes; George I Papakostas
Journal:  Brain Stimul       Date:  2017-09-23       Impact factor: 8.955

4.  Bupropion and Naltrexone in Methamphetamine Use Disorder.

Authors:  Madhukar H Trivedi; Robrina Walker; Walter Ling; Adriane Dela Cruz; Gaurav Sharma; Thomas Carmody; Udi E Ghitza; Aimee Wahle; Mora Kim; Kathy Shores-Wilson; Steven Sparenborg; Phillip Coffin; Joy Schmitz; Katharina Wiest; Gavin Bart; Susan C Sonne; Sidarth Wakhlu; A John Rush; Edward V Nunes; Steven Shoptaw
Journal:  N Engl J Med       Date:  2021-01-14       Impact factor: 91.245

5.  A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.

Authors:  G I Papakostas; K Johe; H Hand; A Drouillard; P Russo; G Kay; R Kashambwa; B Hoeppner; M Flynn; A Yeung; M A Martinson; M Fava
Journal:  Mol Psychiatry       Date:  2019-01-09       Impact factor: 15.992

6.  John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials.

Authors:  Shannon M Smith; Maurizio Fava; Mark P Jensen; Omar B Mbowe; Michael P McDermott; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2020-09       Impact factor: 7.926

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.